Thesis (Ph.D)-Cairo Univsersity,2021

Bibliography: P. 68-92

Diabetes mellitus is a group of metabolic diseases -multi-systemic disorder- characterized by
hyperglycemia resulting from defects in insulin secretion. The therapeutic treatment with bone
marrow mesenchymal stem cells “BM-MSCs” has a promising value in the management of kidney,
liver and pancreatic degeneration. Fifty male rats were used in this experiment; 5 rats as a source
of BM-MSCs, 5 rats (STZ-diabetic) as the cell tracking and the other 40 rats were randomly
assigned into 4 equal groups; normal control (I), stem cell (II), untreated diabetic (III), and treated
diabetic (BM-MSCs) (IV). To induce DM, rats were intraperitoneally injected single dose of
streptozotocin (STZ) (55 mg/kg BW). The BM-MSCs were collected from 10 rats’ bone marrow,
cultured, characterized using flow cytometry analysis and labeled with Qtracker 655 cell labeling.
BM-MSCs were transplanted in treated diabetic at the 7th day of STZ injection. Rats were
euthanized 4 weeks after STZ injection. Blood samples were collected at the end of experiment
(4th week of BM-MSCs transplantation). The pancreas, kidney and liver tissues were collected.
Hemogram, biochemical parameters (liver & Kidney function tests), insulin gene expression and
histopathological examination of pancreas, liver and kidney, were performed for all experimental
groups. Untreated diabetic group showed significant disturbances in liver, kidney and pancreatic
functions with excessive production of inflammatory cytokine (TNF-α) in kidney tissues and
increased oxidative stress in liver tissues. The BM-MSCs treated diabetic group showed significant
improvement in organs functions, insulin gene expression as well as hematological and
histopathological examinations. In conclusion, treatment with BM-MSCs in diabetic rats improved
the diabetic profile and ameliorated some of its complications.

Issues also as CD.

Text in English and abstract in Arabic & English.